First Amendment to Employment Agreement

Exhibit 10.18

First Amendment to Employment Agreement

WHEREAS, MYMD Pharmaceuticals. Inc (the “Company”) and Xxxx X. Xxxxxx, Esq. (“Employee”) (collectively “the Parties”) entered into an Employment Agreement dated September 21, 2020 (“Agreement”); and

WHEREAS, for good and valuable consideration the Parties hereby wish to amend the Agreement as follows:

Exhibit “C” to the Agreement is replaced with the Exhibit “C” appended hereto.

MYMD Pharmaceuticals, Inc.

/s/ Xxxxx X. XxXxxxx

By: Xxxxx X. XxXxxxx, CEO

Xxxx X. Xxxxxx, Esq.

/s/ Xxxx X. Xxxxxx, Esq.

1

EXHIBIT “C”

Milestone Bonuses due upon achievement of milestones

Set forth below is the schedule pursuant to which the Employee will be paid $20,000 at the time each of the pending patent applications are issued to the Company. Each bonus will be paid 30 days after receipt of the Issued Patent.

Title		Assignee		App. No.		Estimated (Actual) Issuance
Methods of Reversing Normal Aging Process and Extending Lifespan		MyMD Pharmaceuticals, Inc.		16/680,677		2Q 2021
Pharmaceutical Salts of Isomyosmine and Pharmaceutical Compositions Containing Same		MyMD Pharmaceuticals, Inc.		16/672,714		(10/20/2020)
Method of Regulating Tumor Necrosis Factor-alpha (TNF-α) for Treating Cancers, Autoimmune Disorders, and Other Disorders Associated with Chronic Inflammation		MyMD Pharmaceuticals, Inc.		16/785,747		(11/17/2020)
Method of Treating Viral Infections		MyMD Pharmaceuticals, Inc.		16/791,290		(9/29/2020)
Method of Treating Coronavirus		MyMD Pharmaceuticals, Inc.		16/792,492		1Q 2021
Methods of Regulating Oxidoreductase for Treatment of Aging and Age-related Disorders		MyMD Pharmaceuticals, Inc.		16/928,255		4Q 2021
Method of Treating Disorders Associated with Chronic Inflammation		MyMD Pharmaceuticals, Inc.		17/084,012		1Q 2022
Synthetic Cannabinoid Compounds for Treatment of Substance Addiction and Other Disorders		Supera Pharmaceuticals, Inc.		16/612,472		1Q 2021

2